Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: CrazyPete who wrote (16910)	5/23/2005 2:31:47 PM
From: DewDiligence_on_SI	Respond to of 52153

My 5->4 example is the worst case, but that’s all we can assume. I maintain that most BP’s would not have designed a trial with the kind of straw-man-like endpoint used in the Vivitrex study. It would have been more illuminating to define a “positive” day as one with, say, three fewer drinks than a given patient’s baseline average.

To: CrazyPete who wrote (16910)	5/23/2005 2:51:46 PM
From: Biomaven	Respond to of 52153

I have the original JAMA article - I can email to anyone who is interested. It doesn't have a lot of raw data. One comment in the article is that the 25% reduction in median heavy-drinking days is misleading - it is skewed by the very heavy drinkers with a lot of events. The typical individual participating in the study had a 48% reduction in median percentage of days with heavy-drinking compared with placebo. For males the improvement is better - looks like about 2 days per month vs 7 on placebo. You are never going to see great statistics out of an alcoholism study. Too much noise, lack of compliance, placebo effect. Peter